Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 859-865

  Zegarac, M ^a   Nikolic, S ^a   Gavrilovic, D ^a   Jevric, M ^a   Kolarevic, D ^a   Nikolic Tomasevic, Z ^a   Kocic, M ^a   Djurisic, I ^a   Inic, Z ^a   Ilic, V ^a   Santrac, N ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Breast cancer; Disease free survival; Liver metastasis; Overall survival; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; LIVER LOBECTOMY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS RESECTION; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PREDICTIVE VALUE; RADIOFREQUENCY ABLATION;

ADULT; AGED; BREAST NEOPLASMS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MASTECTOMY; METASTASECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84893133765     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Elias D, Di Pietroantonio D. Surgery for liver metastases from breast cancer. HPB 2006;8:97-9.
2. Bockhorn M, Frilling A, Brusche C et al. Outcome after resection of breast cancer liver metastases. Int J Hepatol 2010;39-43.
3. Sacamoto Y, Yamamoto J, Yoshimoto M et al. Hepatic resection for metastatic breast cancer:Prognostic analysis of 34 patients. World J Surg 2005;29:524-527. (Pubitemid 41125381)
4. Lubrano J, Roman H, Tarrab S et al. Liver resection for breast cancer metastasis:Does it improve survival? Surgery Today 2008;38:293-299. (Pubitemid 351661111)
5. Adam R, Aloia T, Krissat J et al. Is liver resection jus-tified for patients with hepatic metastases from breast cancer? Ann Surg 2006;244:897-908.
6. Groeschl RT, Nachmany I, Steel JL et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer:a multi-institutional analysis. J Am Coll Surg 2012;214:769-777.
7. Selzner M, Morse MA, Vredenburgh JJ et al. Liver me-tastases from breast cancer:long-term survival after curative resection. Surgery 2000;127:383-389. (Pubitemid 30225989)
8. Eichbaum MHR, Kaltwasser M, Bruckner et al. Prognostic factors for patients with liver metastases from breast cancer. BCRT 2006;96:53-62.
9. Naomoto Y, Sadamori H, Matsukawa H et al. Multiple liver metastases of breast cancer:Report of a case successfully treated with hormone-cytokine-chemo- therapy, Jpn J Clin Oncol 1999;29:390-394.
10. Elias D, Maisonnette F, Druet-Cabanac Met al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 2003;185:158-164. (Pubitemid 36143907)
11. Leake R, Barnes D, Pinder S et al. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol. J Clin Pathol 2000;53:634-635.
12. Martinez SR, Young Sh, Giuliano A et al. The utility of estrogen receptor, progesterone receptor, and Her-2/ neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am J Surg 2006;191:281-286.
13. Abbott DE, Brouquet A, Mittendorf EA et al. Resection of liver metastases from breast cancer:estrogen receptor status and response to chemotherapy before me-tastasectomy define outcome. Surgery 2012;151:710-716.
14. Yamamoto Y, Ibusuki M, Nakano M et al. Clinical significance of basal - like subtype in triple-negative breast cancer. Breast Cancer 2009;16:260-267.
15. Miletic N, Golubicic I, Gavrilovic D et al. The significance of HER-2 amplification and the size and type of pathological unicentric, initially operable clinical stage I and IIA/IIB breast cancer, in determining the treatment strategy, J BUON 2012;17:33-37.
16. Meloni MF, Andreano A, Laeseke PF et al. Breast cancer liver metastases:US-guided percutaneous radiofrequency ablation-intermediate and long-term survival rates. Radiology 2009;253:861-869.